These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22975544)

  • 1. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
    Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
    Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible pre-capillary pulmonary hypertension due to dasatinib.
    Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
    Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary arterial hypertension in patients treated by dasatinib.
    Montani D; Bergot E; Günther S; Savale L; Bergeron A; Bourdin A; Bouvaist H; Canuet M; Pison C; Macro M; Poubeau P; Girerd B; Natali D; Guignabert C; Perros F; O'Callaghan DS; Jaïs X; Tubert-Bitter P; Zalcman G; Sitbon O; Simonneau G; Humbert M
    Circulation; 2012 May; 125(17):2128-37. PubMed ID: 22451584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
    Liu B; Wang Y; Mi Y; Wang J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib (Sprycel) for CML and Ph + ALL.
    Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
    Hong JH; Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Park JE; Jeon HR; Oh YJ; Yi JE; Jung HO; Youn HJ; Kim DW
    Cancer Res Treat; 2015 Oct; 47(4):937-42. PubMed ID: 25648097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
    Keating GM; Lyseng-Williamson KA; McCormack PL; Keam SJ
    BioDrugs; 2013 Jun; 27(3):275-9. PubMed ID: 23549840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pulmonary arterial hypertension.
    Souza R; Jardim C; Humbert M
    Semin Respir Crit Care Med; 2013 Oct; 34(5):560-7. PubMed ID: 24037625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
    Kim JC; Shin SH; Yi HG; Kim SH; Woo SI; Kim DH; Park KS; Kwan J
    Herz; 2013 Dec; 38(8):931-3. PubMed ID: 23430094
    [No Abstract]   [Full Text] [Related]  

  • 12. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Hennigs JK; Keller G; Baumann HJ; Honecker F; Kluge S; Bokemeyer C; Brümmendorf TH; Klose H
    BMC Pulm Med; 2011 May; 11():30. PubMed ID: 21605451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 14. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
    Yun S; Anwer F; Vincelette ND
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
    Rasheed W; Flaim B; Seymour JF
    Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
    [No Abstract]   [Full Text] [Related]  

  • 17. [Reversible dasatinib-related pulmonary arterial hypertension in a CML patient].
    Nagasaki J; Aoyama Y; Nomoto Y; Ido K; Ichihara H; Mugitani A
    Rinsho Ketsueki; 2016 May; 57(5):618-23. PubMed ID: 27263788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
    Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A
    Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
    Taçoy G; Çengel A; Özkurt ZN; Türkoğlu S
    Turk Kardiyol Dern Ars; 2015 Jan; 43(1):78-81. PubMed ID: 25655855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.